Phase 4Status unknown
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
A Post-marketing Clinical Study of a Third Dose of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Beijing): Immunogenicity, Safety and Antibody Persistence Assessments in Patients With Hypertension and/or Diabetes
- Sponsor
- China National Biotec Group Company Limited (Industry)
- Enrollment
- 1,440 planned
- Conditions
- COVID-19 Pneumonia
- Interventions
- Covid-19 vaccine (0-1-4 schedule); Covid-19 vaccine (0-1-6 schedule)
- Ages
- adults, older adults
- Registry
- NCT05104333
Full record on ClinicalTrials.gov
From the registry
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
Primary outcomes
- Seroconversion rate
- Neutralizing antibody level
History
Study completion
Primary completion
Started
Registered